|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MLLT6 |
Gene summary for MLLT6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MLLT6 | Gene ID | 4302 |
| Gene name | MLLT6, PHD finger containing | |
| Gene Alias | AF17 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0002028 | UniProtAcc | A0A087WW39 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4302 | MLLT6 | GSM4909290 | Human | Breast | IDC | 2.04e-44 | 9.83e-01 | 0.2096 |
| 4302 | MLLT6 | GSM4909292 | Human | Breast | IDC | 3.38e-17 | 1.08e+00 | 0.1236 |
| 4302 | MLLT6 | GSM4909293 | Human | Breast | IDC | 4.50e-63 | 8.90e-01 | 0.1581 |
| 4302 | MLLT6 | GSM4909296 | Human | Breast | IDC | 1.89e-03 | -1.44e-01 | 0.1524 |
| 4302 | MLLT6 | GSM4909311 | Human | Breast | IDC | 2.75e-09 | -1.21e-01 | 0.1534 |
| 4302 | MLLT6 | GSM4909312 | Human | Breast | IDC | 2.14e-02 | -1.30e-01 | 0.1552 |
| 4302 | MLLT6 | GSM4909319 | Human | Breast | IDC | 1.13e-10 | -1.13e-01 | 0.1563 |
| 4302 | MLLT6 | GSM4909321 | Human | Breast | IDC | 2.29e-04 | -1.11e-01 | 0.1559 |
| 4302 | MLLT6 | NCCBC5 | Human | Breast | DCIS | 3.15e-02 | 1.05e-01 | 0.2046 |
| 4302 | MLLT6 | P1 | Human | Breast | IDC | 1.79e-06 | 1.06e-01 | 0.1527 |
| 4302 | MLLT6 | DCIS2 | Human | Breast | DCIS | 2.62e-50 | 2.57e-01 | 0.0085 |
| 4302 | MLLT6 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.65e-02 | 3.46e-01 | -0.0811 |
| 4302 | MLLT6 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.58e-09 | 6.24e-01 | -0.059 |
| 4302 | MLLT6 | HTA11_546_2000001011 | Human | Colorectum | AD | 6.46e-04 | 3.95e-01 | -0.0842 |
| 4302 | MLLT6 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.65e-02 | 3.45e-01 | 0.0338 |
| 4302 | MLLT6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.62e-16 | 6.21e-01 | 0.0674 |
| 4302 | MLLT6 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.01e-04 | 4.19e-01 | 0.294 |
| 4302 | MLLT6 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.34e-07 | 6.07e-01 | 0.281 |
| 4302 | MLLT6 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.92e-21 | 7.29e-01 | 0.3859 |
| 4302 | MLLT6 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.66e-03 | 5.77e-01 | 0.2585 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005087813 | Breast | IDC | regulation of body fluid levels | 50/1434 | 379/18723 | 1.12e-04 | 2.10e-03 | 50 |
| GO:001095913 | Breast | IDC | regulation of metal ion transport | 52/1434 | 406/18723 | 1.76e-04 | 2.97e-03 | 52 |
| GO:00432703 | Breast | IDC | positive regulation of ion transport | 36/1434 | 275/18723 | 1.11e-03 | 1.22e-02 | 36 |
| GO:005087823 | Breast | DCIS | regulation of body fluid levels | 50/1390 | 379/18723 | 5.17e-05 | 1.06e-03 | 50 |
| GO:001095921 | Breast | DCIS | regulation of metal ion transport | 50/1390 | 406/18723 | 2.86e-04 | 4.22e-03 | 50 |
| GO:004327011 | Breast | DCIS | positive regulation of ion transport | 34/1390 | 275/18723 | 2.35e-03 | 2.13e-02 | 34 |
| GO:00030144 | Breast | DCIS | renal system process | 16/1390 | 110/18723 | 7.16e-03 | 4.85e-02 | 16 |
| GO:0002028 | Colorectum | AD | regulation of sodium ion transport | 36/3918 | 90/18723 | 2.89e-05 | 5.37e-04 | 36 |
| GO:0010765 | Colorectum | AD | positive regulation of sodium ion transport | 17/3918 | 35/18723 | 2.48e-04 | 3.13e-03 | 17 |
| GO:0050878 | Colorectum | AD | regulation of body fluid levels | 108/3918 | 379/18723 | 2.54e-04 | 3.20e-03 | 108 |
| GO:0003014 | Colorectum | AD | renal system process | 35/3918 | 110/18723 | 4.85e-03 | 3.27e-02 | 35 |
| GO:0055067 | Colorectum | AD | monovalent inorganic cation homeostasis | 45/3918 | 151/18723 | 6.19e-03 | 3.88e-02 | 45 |
| GO:0031056 | Colorectum | AD | regulation of histone modification | 45/3918 | 152/18723 | 7.05e-03 | 4.31e-02 | 45 |
| GO:00020282 | Colorectum | MSS | regulation of sodium ion transport | 32/3467 | 90/18723 | 9.56e-05 | 1.50e-03 | 32 |
| GO:00508782 | Colorectum | MSS | regulation of body fluid levels | 99/3467 | 379/18723 | 1.40e-04 | 2.07e-03 | 99 |
| GO:00107652 | Colorectum | MSS | positive regulation of sodium ion transport | 15/3467 | 35/18723 | 7.59e-04 | 8.09e-03 | 15 |
| GO:0016570 | Colorectum | MSS | histone modification | 113/3467 | 463/18723 | 8.37e-04 | 8.68e-03 | 113 |
| GO:00310562 | Colorectum | MSS | regulation of histone modification | 41/3467 | 152/18723 | 6.41e-03 | 4.27e-02 | 41 |
| GO:00020284 | Colorectum | FAP | regulation of sodium ion transport | 33/2622 | 90/18723 | 6.51e-08 | 4.54e-06 | 33 |
| GO:00107654 | Colorectum | FAP | positive regulation of sodium ion transport | 16/2622 | 35/18723 | 5.99e-06 | 1.90e-04 | 16 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MLLT6 | SNV | Missense_Mutation | novel | c.877N>A | p.Glu293Lys | p.E293K | protein_coding | tolerated(0.08) | probably_damaging(0.953) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MLLT6 | insertion | Frame_Shift_Ins | novel | c.997_998insGTAAAGA | p.Ser333CysfsTer24 | p.S333Cfs*24 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |||
| MLLT6 | insertion | Frame_Shift_Ins | novel | c.998_999insACTGACACTTATCGACGTTGAGA | p.Ser334LeufsTer123 | p.S334Lfs*123 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |||
| MLLT6 | deletion | Frame_Shift_Del | novel | c.609_619delCAGCATGGGGG | p.Ser204ArgfsTer42 | p.S204Rfs*42 | protein_coding | TCGA-B6-A409-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |||
| MLLT6 | deletion | Frame_Shift_Del | novel | c.1382_1392delNNNNNNNNNNN | p.Thr461ArgfsTer92 | p.T461Rfs*92 | protein_coding | TCGA-C8-A12V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| MLLT6 | SNV | Missense_Mutation | novel | c.235N>C | p.Asp79His | p.D79H | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MLLT6 | SNV | Missense_Mutation | novel | c.228N>C | p.Lys76Asn | p.K76N | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| MLLT6 | SNV | Missense_Mutation | novel | c.1831C>G | p.Gln611Glu | p.Q611E | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| MLLT6 | SNV | Missense_Mutation | novel | c.1927N>A | p.Glu643Lys | p.E643K | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | |
| MLLT6 | SNV | Missense_Mutation | novel | c.1330N>T | p.Arg444Trp | p.R444W | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |